Aims Many clinical trials conducted in the 1970s and early 1980s have shown that the long-
term use of beta-blockers after an acute myocardial infarction significantly reduces mortality …

Aims Long-term beta-blockade reduced mortality after acute myocardial infarction by about a
quarter in a series of published trials. Representative data on beta-blocker use for …

The objective of the Beta-Blocker Pooling Project (BBPP) was to collect and analyse data
from the major long-term secondary prevention trials in order to determine whether there are …

Beta-blockers significantly decrease the risk of mortality in patients after myocardial
infarction (MI). Furthermore, beta-blockers reduce the risk of reinfarction and mortality in both …

Based on selected patient populations, several randomized trials have shown beta blockers
to decrease mortality after acute myocardial infarction (AMI). The purpose of this study was …

Patients (especially older patients) with acute myocardial infarction (MI) treated with or
without thrombolytic therapy, who have no contraindications to beta-blockers, should be …

PURPOSE: To assess whether implementation of guidelines increases the prescription of
drugs, particularly β blockers, recommended for secondary prevention after acute …

Objectives: To assess the effectiveness of β blockers in short term treatment for acute
myocardial infarction and in longer term secondary prevention; to examine predictive factors …

Several large, prospective, randomized, clinical trials involving more than 11,500 patients
testing five beta-blockers with respect to efficacy in reducing mortality after myocardial …

A large number of pharmacological trials have been carried out, attempting to reduce the
mortality (10-15%) in the year following of an acute myocardial infarction (MI) and/or the …